FDA: New side effect warning on GLP-1 drugs

GLP-1 drugs will now carry a warning for a rare, but potentially dangerous side effect that can lead to vision loss, the FDA says. Dr. Rachel Pessah-Pollack joins CBS News' "The Daily Report" to discuss.

• Nov 10

FDA warns of rare vision-loss side effect from GLP-1 drugs

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.

• Nov 9

FDA announces new GLP-1 warning label

The FDA announced that GLP-1 weight loss drugs will now include warning labels indicating a potential increased risk of vision loss.

• Nov 9

RFK Jr. to ease access to unapproved peptides, draft policy states

Health and Human Services Secretary Robert F. Kennedy Jr. took steps Wednesday that could open up access to certain unapproved peptide drugs that are being promoted for wellness.

• Oct 28

"Kindness mob" helps drown out hate comments

"The Kindness Mob," a group of half-a-million people, is helping online strangers recover from hate comments. Steve Hartman goes "On the Road" to meet one woman who benefited from the mob's help.

• Oct 23

More people now use GLP-1s to lose weight than for other health issues

Growing usage of GLP-1 drugs for weight loss is reshaping how consumers shop for food and clothes, according to consulting firm EY-Parthenon.

• Oct 22

We tested vials sold as weight loss drugs

CBS News bought and tested vials marketed as an experimental weight loss drug from several sources to find out what was actually inside. Adam Yamaguchi shares the results on "CBS Mornings."

• Oct 21

We tested vials sold as weight loss drugs

CBS News bought and tested vials marketed as an experimental weight loss drug from several sources to find out what was actually inside. Adam Yamaguchi shares the results on "CBS Mornings."

• Oct 21

Is a bootleg weight-loss drug to blame for 2 reported deaths?

While unverified, the reports come amid growing efforts to clamp down on illicit sales of the experimental weight-loss drug retatrutide.

• Oct 13

Weight loss drug possibly linked to 2 deaths

Two recent deaths reported to the FDA could be linked to Retatrutide, an unapproved weight-loss drug made popular on social media. CBS News investigative reporter Daniel Gilbert has the latest.

• Oct 13

Black market weight-loss drug sparks concern

Two deaths were reported to the U.S. Food and Drug Administration that may be tied to the use of bootleg weight-loss drugs, documents reviewed by CBS News show.

• Oct 13

How GLP-1 drugs could help bad money habits

Dr. Carolina Haass-Koffler, associate professor of psychiatry at Brown University, joins "The Daily Report" to explain how GLP-1 drugs could be used to treat addictions beyond excessive eating.

• Oct 8

What to know about retatrutide

Retatrutide is the latest experimental weight-loss drug with promising clinical trial results, but it's not yet approved by the FDA. Dr. Céline Gounder has the latest.

• Sep 30

Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs?

The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."

• Sep 24

Experimental weight loss drug sold illegally

Retatrutide, an experimental weight loss drug still undergoing clinical trials at Eli Lilly, is being marketed online and illegally sold to U.S. clients, a CBS News investigation found. CBS News investigative reporter and producer Daniel Gilbert has the story.

• Sep 16

Access expanding for experimental weight loss drug

Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safety, who is eligible for the medication and more.

• Aug 4

GLP-1s are linked to a 17% drop in worker sick leave, new study finds

Here's how weight-loss drugs like Ozempic and Wegovy could reduce worker illness and save companies money.

• Jul 21

Novo Nordisk sues Eli Lilly, accusing it of false advertising

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.

• Jul 21

What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug

It isn't approved by the FDA, but we found an experimental weight-loss drug called retatrutide for sale at a local convenience store.

• Jul 2

Here's what to know about Medicare's new GLP-1 weight-loss drug program

For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.

• Jun 29

Extreme heat and GLP-1 drugs

More than 10% of Americans say they use GLP-1 drugs. But experts warn some side effects from the drugs could lead to dehydration, especially in extreme heat. Nutritionist Keri Glassman explains.

• Jun 29

Benefits and risks of GLP-1 drugs for kids

Childhood and teen obesity rates have soared to record highs with about 1 in 5 living with obesity. The FDA has approved GLP-1 drugs for weight loss among kids 12 and older. Dr. Rachel Pessah-Pollack explains the risks and benefits, who may be a candidate and more.

• Jun 23

Weight loss drug use during pregnancy

CBS News medical correspondent Dr. Celine Gounder breaks down findings from a new study that takes a close look at popular GLP-1 weight loss drugs and their use during early pregnancy.

• Jun 9

Safety concerns over weight loss drug

There's a new safety concern about doctors prescribing one experimental weight loss treatment, retatrutide, that hasn't even been FDA approved yet. Adam Yamaguchi reports.

• Jun 8

Doctors promote experimental weight loss drug

The weight loss drug retatrutide has been touted as "Ozempic on steroids." It's still in clinical trials and not approved by the FDA, but a CBS News investigation found that hasn't stopped doctors from offering it, and it could come with serious side effects. Adam Yamaguchi reports.

• Jun 8

Show More